Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Claudin 18.2 is a validated target in various solid tumors.
• Next-generation cancer therapies are actively exploring novel targets and mechanisms.
• Bispecific antibodies represent a promising therapeutic modality in oncology.

Purpose of the Study:

• To investigate the potential of bispecific antibodies linking Claudin 18.2 to conditional 4-1BB activation.
• To evaluate the efficacy of tumor microenvironment-confined costimulation for T-cell enhancement.
• To assess the safety profile concerning systemic toxicity.

Main Methods:

• Development and application of bispecific antibodies targeting Claudin 18.2.
• Utilizing conditional 4-1BB activation strategies.
• Assessing T-cell function and tumor microenvironment modulation.

Main Results:

• Bispecific antibodies demonstrated the ability to link Claudin 18.2 with 4-1BB activation.
• Conditional costimulation was successfully confined to the tumor microenvironment.
• Enhanced T-cell function and anti-tumor activity were observed.

Conclusions:

• Bispecific antibodies targeting Claudin 18.2 with conditional 4-1BB activation are a viable therapeutic strategy.
• Confining costimulation to the tumor microenvironment enhances efficacy and minimizes systemic toxicity.
• This approach holds promise for next-generation solid tumor treatments.